Dr. Michael Danso is an Attending Physician and Research Director at Virginia Oncology Associates, a legacy-US Oncology Research and Sarah Cannon Research Institute site.
Dr. Danso began his formal medical education at The Royal Free Hospital School of Medicine in London before going on to complete his internship and residency at Pennsylvania Hospital, University of Pennsylvania Health System. Dr. Danso then completed his Fellowship training at Memorial Sloan-Kettering Cancer Center where he served as Chief Fellow, made significant contributions to medical education by editing the "Hematology and Oncology Pearls" textbook, and helped define the important role of the Androgen Receptor in Triple Negative Breast Cancer.
Dr. Danso was later recruited by Virginia Oncology Associates to lead their Breast Cancer Research Program. Under his leadership, practice changing research opportunities were made available to the community including Keynote-522 which saw the initial adoption of immunotherapy in early-stage TNBC, the original ASCENT study which ushered in the era of antibody-drug conjugates for mTNBC and monarchE which added a CDK4/6i to help improve survival for high-risk ER-positive patients.
Dr. Danso is also the Chair of the Oncology Service line for the Sentara Cancer Network in Hampton Roads and Associate Chair of Breast Cancer Research for the Sarah Cannon Research Institute. Dr. Danso has served in numerous ASCO committees over the years, including chair for the metastatic breast cancer scientific committee for the 2023 Annual ASCO Meeting where he was also honored as a member of the 2023 class of Fellows.